A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1436-3305
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer ; volume:25 ; number:3 ; day:7 ; month:3 ; year:2022 ; pages:619-628 ; date:5.2022
Gastric cancer ; 25, Heft 3 (7.3.2022), 619-628, 5.2022
- Creator
-
Hasegawa, Hirotaka
Shitara, Kohei
Takiguchi, Shuji
Takiguchi, Noriaki
Ito, Seiji
Kochi, Mitsugu
Horinouchi, Hidehito
Kinoshita, Takahiro
Yoshikawa, Takaki
Muro, Kei
Nishikawa, Hiroyoshi
Suna, Hideaki
Kodera, Yasuhiro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10120-022-01286-w
- URN
-
urn:nbn:de:101:1-2022070120184893219764
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hasegawa, Hirotaka
- Shitara, Kohei
- Takiguchi, Shuji
- Takiguchi, Noriaki
- Ito, Seiji
- Kochi, Mitsugu
- Horinouchi, Hidehito
- Kinoshita, Takahiro
- Yoshikawa, Takaki
- Muro, Kei
- Nishikawa, Hiroyoshi
- Suna, Hideaki
- Kodera, Yasuhiro
- SpringerLink (Online service)
Other Objects (12)
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial